This Article Full Text Full Text (PDF) Supplementary Data Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Buganim, Y. Articles by Rotter, V. Search for Related Content PubMed PubMed Citation Articles by Buganim, Y. Articles by Rotter, V.

Mutant p53 Protects Cells from 12-O-Tetradecanoylphorbol-13-Acetate–Induced Death by Attenuating Activating Transcription Factor 3 Induction

¹ Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel; ² Department of Life Science, Bar-Ilan University, Ramat Gan, Israel; and ³ Department of General Surgery B, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Requests for reprints: Varda Rotter, Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel. Phone: 972-8-9344070; Fax: 972-8-9465265; E-mail: varda.rotter{at}weizmann.ac.il.

Mutations in p53 are ubiquitous in human tumors. Some p53 mutations not only result in loss of wild-type (WT) activity but also grant additional functions, termed "gain of function." In this study, we explore how the status of p53 affects the immediate response gene activating transcription factor 3 (ATF3) in the 12-O-tetradecanoylphorbol-13-acetate (TPA)-protein kinase C (PKC) pathway. We show that high doses of TPA induce ATF3 in a WT p53-independent manner correlating with PKCs depletion and cell death. We show that cells harboring mutant p53 have attenuated ATF3 induction and are less sensitive to TPA-induced death compared with their p53-null counterparts. Mutagenesis analysis of the ATF3 promoter identified the regulatory motifs cyclic AMP-responsive element binding protein/ATF and MEF2 as being responsible for the TPA-induced activation of ATF3. Moreover, we show that mutant p53 attenuates ATF3 expression by two complementary mechanisms. It interacts with the ATF3 promoter and influences its activity via the MEF2 site, and additionally, it attenuates transcriptional expression of the ATF3 activator MEF2D. These data provide important insights into the molecular mechanisms that underlie mutant p53 gain of function. (Cancer Res 2006; 66(22): 1750-9)

This article has been cited by other articles:

				E. Kalo, Y. Buganim, K. E. Shapira, H. Besserglick, N. Goldfinger, L. Weisz, P. Stambolsky, Y. I. Henis, and V. Rotter Mutant p53 Attenuates the SMAD-Dependent Transforming Growth Factor {beta}1 (TGF-{beta}1) Signaling Pathway by Repressing the Expression of TGF-{beta} Receptor Type II Mol. Cell. Biol., December 1, 2007; 27(23): 8228 - 8242. [Abstract] [Full Text] [PDF]